Ed is an Executive Board member, and past secretary of that board. With more than 30 years in the pharmaceutical industry, Ed has led several drug development projects involving prescription and over-the-counter (OTC) products as well as transitioning prescription products to OTC. His experience includes international assignments, notably in the Pacific Rim.
Ed has ET and can trace it through several generations of his family. In addition, as a result of his professional expertise, he understands the limited options for treating the condition.
The IETF relies on his understanding of drug development, including regulatory and political processes, to help determine and reach both short- and long-term goals. Ed has experience in marketing/evaluating business development opportunities for potential ET treatment options based on credible medical evidence.